Latest news with #JohnLeonard
Time of India
02-06-2025
- Sport
- Time of India
Florida Panthers set sights on Stanley Cup victory as Charlotte Checkers move toward Calder Cup Final
Florida Panthers (via Getty Images) T he Florida Panthers are pursuing their much-awaited Stanley Cup win and their AHL affiliate, the Charlotte Checkers, are making history on their own in the Calder Cup Playoffs. For the first time since coming together in 2020, both teams are within reach of championship glory—an accomplishment that could replicate an unusual feat unseen in almost 30 years in professional hockey. Charlotte Checkers overwhelm Laval Rocket to sit one win shy of Calder Cup Final undefined The Florida Panthers may not be the only team in the playoffs spotlight, as the Charlotte Checkers are within a win of heading to the Calder Cup Final with a 5-1 thumping of the Laval Rocket in Game 3 of the Eastern Conference Finals. On Sunday, the team effort was visible with Riley Bezeau scoring twice, including one during a four-goal second period, as John Leonard, Will Lockwood, and Sandis Vilmanis also scored to make the game far out of reach for the AHL affiliate Laval Rocket of the Montreal Canadiens. Goaltender Kaapo Kahkonen was again phenomenal with 22 saves, supporting Charlotte to its seventh consecutive playoff victory. The Checkers have now scored 15-4 in this best-of-seven series against Laval. 'Our guys have done it all year,'' Charlotte Checkers head coach Geordie Kinnear said. 'That's a great team,'' Bezeau said. 'They finished first in their division; they're not going to go away, and we know that. We've just got to stick to our game plan and keep going.' If Charlotte sweeps the series at home Tuesday night, and if the Florida Panthers keep their Stanley Cup Final quest alive, the two teams might duplicate a task last accomplished in 1995 when the New Jersey Devils and Albany River Rats captured the Stanley Cup and Calder Cup, respectively. Meanwhile in the Western Conference, the Abbotsford Canucks lead 2-0 against the Texas Stars and the series heads to Austin for Game 3. Also read: Brad Marchand eyes the second Stanley Cup in a career-redefining run with the Florida Panthers As the Florida Panthers eye a Stanley Cup championship, the Charlotte Checkers are forging an equally impressive argument for a Calder Cup Final appearance. If both teams win their respective titles, it would be a historic double victory for the organization, helping to make this year one of the most successful in Florida's hockey history.
Yahoo
29-05-2025
- General
- Yahoo
Charlotte Checkers lead Eastern Conference finals after win over Laval
The Charlotte Checkers are back in action Thursday night after earning a one-game lead in the Eastern Conference finals. The Checkers topped the Laval Rockets Wednesday night, 5-1. John Leonard scored his third goal of the preseason, setting an all-time franchise record. Advertisement Game two at Laval is set for 7 p.m. VIDEO: Charlotte Checkers announce new ownership
CBC
22-05-2025
- Business
- CBC
Controversy on the cul-de-sac: Residents, developer at odds over Margaret's Place plans
A developer is billing its plan to build a six-storey apartment building on Margaret's Place as part of the effort to ease the housing crisis — but a petition signed by 121 residents is asking St. John's city council to reject the project. John Leonard, an organizer of the petition, says residents aren't against development in the area — but they are against the current proposal. "Given the concerns that exist with historical problems, maintenance problems, servicing problems, fire protection and snow clearing and so on and so forth, we say 'Please listen, this is a problem,'" Leonard told CBC Radio's The St. John's Morning Show. Stonemount Enterprises Ltd. is proposing a 60-unit apartment building and eight new townhouses at the end of Margaret's Place, a long cul-de-sac between the Rabbittown and Georgestown neighbourhoods. Dozens of townhouses and two condo buildings already exist along Margaret's Place, which is behind Holy Heart High School and Brother Rice Junior High. City council has already granted permission for another housing development. Leonard believes the addition of the Stonemount development would qualify as "overdevelopment." He says the current street is already abnormally narrow and has ongoing congestion issues — especially during the winter. He believes the Stonemount development would exacerbate the problem, and potentially create issues for emergency vehicle access. Stonemount declined an interview request, but in a statement spokesperson Janine Walsh says the developers believe the proposal is well-aligned with the layout of the area, and will deliver "feasible and affordable" residential units. "Our intent has consistently been to work collaboratively with residents to achieve a mutually beneficial outcome," she said. However, Walsh says the developers were caught off-guard by the petition, which was presented to city council a few weeks ago. "We would have welcomed a more open and transparent approach to these discussions." Stonemount is also in a dispute with the McKee's Grove condo board over parking. "McKees Grove Condominium currently utilizes services and access points that are not supported by legal easements, and portions of their entrance and parking lot fall outside their property boundaries," Walsh said. Development doldrums The controversy over the Stonemount development is the latest in a series of disputes over housing proposals in existing neighbourhoods. In March, St. John's city council voted to exempt a proposal for a 10-storey apartment building on New Cove Road from the city's set-back requirement, despite pushback from area residents. Deputy Mayor Sheilagh O'Leary was one of just two council members to vote against the exemption, citing resident concerns. O'Leary also has concerns about the Stonemount development, and agreed to present the petition at a recent city council meeting. "This is not a typical cul-de-sac. This is something that we […] have really not seen in our city and as a result, it has caused a lot of conflict within the area," she said. Still, O'Leary says she isn't set on voting against the project. "I think really what needs to happen is a conversation," she said. She says the city already plans to widen Belvedere's Lane to create emergency vehicle access between Margaret's Place and Bonaventure Avenue. O'Leary says she's also concerned about the lack of open and green space for residents and students from the nearby schools. Currently, students use the future site of the Stonemount development to play sports. The Stonemount property also contains the former St. Michael's Convent, a registered historic structure. According to Heritage N.L., the building could be the second oldest in St. John's, but for years it's been falling into neglect. O'Leary said she's worried it could get worse. "We have seen this happen over and over again. This is going to be demolition by neglect. That's the bottom line," she said. In a followup email, Walsh said the Stonemount developers have heard from parties interested in purchasing the former convent. However, according to Walsh, the ongoing dispute has prevented that sale from proceeding. "As a result, despite our efforts to improve the property, we are currently unable to proceed, and the convent remains in its current state," she said. Walsh said Stonemount will follow the guidance of its legal counsel while considering next steps for the development.
Yahoo
19-05-2025
- Health
- Yahoo
BI2 Technologies and Support Our Sheriffs Foundation partner with SingleCare to create Sheriff Rx
Free program will provide access to affordable medications to Sheriffs' employees across the nation PLYMOUTH, Mass., May 19, 2025 /PRNewswire/ -- Many people, including those with full-time jobs, often struggle to cover deductibles and copays for prescription drugs, even with insurance. That is why Support Our Sheriffs Foundation™ and BI2 Technologies™ are proud to announce they have partnered with SingleCare® to create Sheriff Rx™. Sheriff Rx™ will provide access to affordable prescription medications, ensuring greater health and financial stability. The Sheriff Rx™ prescription discount card is completely free. The discounts and savings on medications are provided voluntarily by more than 35,000 participating pharmacies that agree to provide prices similar to what they give large insurance companies. The card has no eligibility requirements and is available to anyone. There are no forms to fill out, waiting period or registration. If employees and their families already have prescription drug coverage, Sheriff Rx™ can be used to obtain savings on prescription drugs that may be excluded by your insurance plan or are not covered because you have exceeded your insurance plan's maximum limits. In some instances, members might find that the Sheriff Rx™ price is lower than many insurance copayment amounts. SingleCare® partners with some of the most respected community groups and health care providers in the country, including United Way Worldwide, National Council for Behavioral Health, Mental Health America, and American Heart Association, among thousands of other community organizations. "When people can afford their prescriptions, they end up saving money on more expensive items like emergency room visits and hospitalizations," said BI2 Technologies Chief Relationship Office John Leonard. "We are excited to work with the Support Our Sheriffs Foundation™ and SingleCare® to provide Sheriff Rx™ at no cost to Sheriffs' employees and their families." SingleCare® is accepted by major pharmacies, including CVS, Rite Aid, Walgreens, Albertsons, Kroger and Walmart, as well as many local retailers. "As we work to support our Sheriffs' Offices across the nation, it is crucial that every employee and their families have access to affordable medications and are empowered to take control of their health," said Support Our Sheriffs Executive Director Mark Lamb. "Sheriff Rx™ is designed to do just that." To see how much you can save, please visit or email John Leonard at jleonard@ About the Support Our Sheriffs Foundation™The Support Our Sheriffs Foundation is made up of current and former law enforcement professionals, businesses and community activists who are dedicated to supporting the mission of Sheriffs Offices across the nation. Donations to the Foundation are used to provide essential resources, financial support, training, and programs that enhance the effectiveness, safety, and well-being of Sheriffs, their employees, their families, and the communities they serve. For more information about the Foundation or to donate, please visit About BI2 Technologies™BI2 Technologies (Biometric Intelligence and Identification Technologies) is an award-winning and recognized leader in the development and implementation of cost-effective, multimodal biometric identity management solutions. BI2 Technologies created and maintains the only national, cloud-based iris biometric network and database. No other organization, public or private, has developed or implemented this capability. About SingleCare®SingleCare® is a free prescription savings service that provides consistently low prices to improve access and adherence to medication. It handles tens of thousands of prescriptions per day and is helping millions of people across the U.S. save a significant amount of money on their prescriptions. Through a combination of innovative technology and direct contracts with pharmacies, SingleCare® allows consumers to access prescription savings at pharmacies near them via the mobile app or discount cards available on SingleCare® partners with the country's leading pharmacy companies, including CVS, Walmart and Walgreens, covering over 35,000 pharmacies nationwide. View original content to download multimedia: SOURCE BI2 Technologies Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
18-05-2025
- Business
- Associated Press
Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting
CAMBRIDGE, Mass., May 18, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced positive two-year follow-up data from the ongoing Phase 1 trial of investigational nexiguran ziclumeran (nex-z) for the treatment of hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Results were shared in an oral presentation on Sunday, May 18 at the 2025 Peripheral Nerve Society (PNS) Annual Meeting in Edinburgh, United Kingdom. The Phase 3 MAGNITUDE-2 trial design of nex-z in ATTRv-PN was also exhibited in a poster presentation. 'We are pleased to share new findings at PNS, which continue to support our growing body of evidence that a single dose of nex-z leads to deep, durable and consistent reductions in serum TTRs, with evidence of disease stability or clinically meaningful improvements in neuropathic impairment measures through two years,' said Intellia President and Chief Executive Officer John Leonard, M.D. 'These data are also the first to show improvement in patients who had previously progressed on patisiran, further validating the hypothesis that increasingly deep reductions in TTR levels may lead to improved outcomes in ATTR amyloidosis.' ATTRv-PN Results * Data cutoff April 11, 2025; ** Data cutoff August 21, 2024; *** Data cutoff April 12, 2024; † N=6; ‡ 24-month data in 19 patients; N/A: Data not available at Month 24 Negative change reflects improvement in the following results: NIS, mNIS+7, Norfolk QoL-DN and NfL Positive change reflects improvement in mBMI Study is ongoing and reported results reflect the available data as of the data cutoff The presentation will be available on the Scientific Publications & Presentations section of About the Nexiguran Ziclumeran (nex-z, also known as NTLA-2001) Clinical Program The global Phase 1 trial is an ongoing open-label, multi-center, two-part study of NTLA-2001 in adults with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN) or transthyretin amyloidosis with cardiomyopathy (ATTR-CM). Part 1 of the ATTRv-PN arm of the study is an open-label, single-ascending dose escalation cohort and Part 2 is an open-label, single-dose expansion cohort. Visit (NCT04601051) for more details. About the MAGNITUDE-2 Study The pivotal Phase 3 MAGNITUDE-2 clinical trial is a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of nexiguran ziclumeran (nex-z) in approximately 50 patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). The primary endpoints of the study are a change in modified neuropathy impairment score and a change in serum TTR levels. Adult patients with ATTRv-PN will be randomized 1:1 to receive a single 55 mg infusion of nex-z or placebo. For more information on MAGNITUDE-2 (NCT06672237), please visit About Nex-z Based on Nobel Prize-winning CRISPR/Cas9 gene editing technology, nex-z has the potential to become the first one-time treatment for transthyretin (ATTR) amyloidosis. Nex-z is designed to inactivate the TTR gene that encodes for the transthyretin (TTR) protein. Interim Phase 1 clinical data showed the administration of nex-z led to consistent, deep and long-lasting TTR reduction. Intellia leads development and commercialization of nex-z as part of a multi-target discovery, development and commercialization collaboration with Regeneron Pharmaceuticals, Inc. About Transthyretin (ATTR) Amyloidosis Transthyretin amyloidosis, or ATTR amyloidosis, is a rare, progressive and fatal disease. Hereditary ATTR (ATTRv) amyloidosis occurs when a person is born with mutations in the TTR gene, which causes the liver to produce structurally abnormal transthyretin (TTR) protein with a propensity to misfold. These damaged proteins build up as amyloid in the body, causing serious complications in multiple tissues, including the heart, nerves and digestive system. ATTRv amyloidosis predominantly manifests as polyneuropathy (ATTRv-PN), which can lead to nerve damage, or cardiomyopathy (ATTRv-CM), which can lead to heart failure. Some individuals without the genetic mutation produce non-mutated, or wild-type TTR proteins that become unstable over time, misfolding and aggregating in disease-causing amyloid deposits. This condition, called wild-type ATTR (ATTRwt) amyloidosis, primarily affects the heart. There are an estimated 50,000 people worldwide living with ATTRv amyloidosis and between 200,000 and 500,000 people with ATTRwt amyloidosis. There is no known cure for ATTR amyloidosis and currently available medications are limited to slowing accumulation of misfolded TTR protein. About Intellia Therapeutics Intellia Therapeutics, Inc. (NASDAQ: NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. Since its inception, Intellia has focused on leveraging gene editing technology to develop novel, first-in-class medicines that address important unmet medical needs and advance the treatment paradigm for patients. Intellia's deep scientific, technical and clinical development experience, along with its people, is helping set the standard for a new class of medicine. To harness the full potential of gene editing, Intellia continues to expand the capabilities of its CRISPR-based platform with novel editing and delivery technologies. Learn more at and follow us @intelliatx. Forward-Looking Statements This press release contains 'forward-looking statements' of Intellia Therapeutics, Inc. ('Intellia' or the 'Company') within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia's beliefs and expectations regarding: the safety, tolerability, efficacy, success and advancement of its clinical programs for nexiguran ziclumeran or 'nex-z' (also known as NTLA-2001) for transthyretin ('ATTR') amyloidosis, including the ability to successfully complete its global Phase 3 MAGNITUDE-2 study for hereditary ATTR amyloidosis with polyneuropathy ('ATTRv-PN') pursuant to its clinical trial applications and investigational new drug submissions; its belief that enrollment continues to progress well in the MAGNITUDE-2 study; its belief that a single dose of nex-z leads to deep, durable and consistent reductions in serum TTR and that increasingly deep reductions in TTR levels leads to improved outcomes; and its expectation to be able to support the submission of a biologics license application for nex-z for the treatment of ATTRv-PN by 2028. Any forward-looking statements in this press release are based on management's current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to Intellia's ability to protect and maintain its intellectual property position; risks related to valid third party intellectual property; risks related to Intellia's relationship with third parties, including its licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; uncertainties related to regulatory agencies' evaluation of regulatory filings and other information related to our product candidates, including nex-z; uncertainties related to the authorization, initiation and conduct of studies and other development requirements for our product candidates, including uncertainties related to regulatory approvals to conduct clinical trials, including our ability to enroll the Phase 3 MAGNITUDE-2 study for ATTRv-PN; the risk that any one or more of Intellia's product candidates, including nex-z, will not be successfully developed and commercialized; the risk that the results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies for the same product candidate or Intellia's other product candidates; and risks related to Intellia's reliance on collaborations, including that its collaboration with Regeneron Pharmaceuticals, Inc. will not continue or will not be successful. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia's actual results to differ from those contained in the forward-looking statements, see the section entitled 'Risk Factors' in Intellia's most recent annual report on Form 10-K and quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in Intellia's other filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law. Intellia Contacts: Investors: Brittany Chaves Senior Manager, Investor Relations [email protected] Media: Matt Crenson Ten Bridge Communications [email protected] [email protected]
